MarketPR
Bristol Myers Squibb Company (BMY) has increased its 2026 revenue outlook for Eliquis to a growth range of 20-25%, up from prior guidance of 10-15%, as the company projects that strong global demand for the co-developed anticoagulant will partially offset broader declines in its legacy portfolio.
The adjustment comes amid a year in which BMY shares have rallied 35.8%, outperforming both the S&P 500 and the industry's 11% growth rate.
The company's top-line momentum is driven primarily by its Growth Portfolio, which accounted for approximately 56% of total revenues in the first half of 2026.
Key contributors include Opdivo Qvantig, which has surpassed $1 billion in annualized revenues as uptake increases across approved tumor types, and Reblozyl, developed in partnership with Merck (MRK), which continues to see solid uptake in first-line MDS-associated anemia.
Keep reading